Phase 2 N=8 Study of Alwextin® Cream in Treating Epidermolysis Bullosa
Epidermolysis Bullosa
Primary: Blister/Erosion Reduction Based on Change in Body Surface Area (BSA) Coverage — 57.25; 39.40; 27.25; 25.45 percentage of BSA involvement
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=239 Long Term Safety of Teriflunomide When Added to Interferon-Beta or Glatiramer Acetate in Patients With Multiple Sclerosis
Multiple Sclerosis
Primary: Overview of Adverse Events [AE] — 35; 35; 33; 39 participants
Phase 2 N=139 A Study to Investigate the Safety and Efficacy of CP-690,550 in Patients With Moderate to Severe Crohn's Disease
Crohn's Disease
Primary: Number of Participants With Clinical Response 70 at Week 4 — 14; 13; 18; 16 participants
Phase 2 N=260 Forced-dose Titration of SPD489 in Adults With Binge Eating Disorder
Binge Eating Disorder
Primary: Change From Baseline in Log Transformed Binge Days Per Week at Week 11 — -1.23; -1.24; -1.49; -1.57 Log days — p=0.8825
Phase 2 N=39 Fludarabine, Cyclophosphamide, and Rituximab in Treating Patients Who Have Chronic Lymphocytic Leukemia
Leukemia
Primary: Overall Response Rate — 22; 2; 8; 4 participants
Phase 2 N=10 Creatine Safety & Tolerability in Huntington's Disease
Huntington's Disease (HD)
Primary: Tolerability — 5 Participants
Phase 2 N=74 Pharmacogenetics of Disulfiram for Cocaine
Cocaine Dependence · Opioid Dependence
Primary: Urine Toxicology for Cocaine. — 84; 68; 56; 67 % cocaine + urines over 2 week blocks
Phase 2 N=12 A New Modified-release Tablet Formulation of Prednisone (Lodotra®) in Patients With Nocturnal Asthma
Asthma
Primary: Total Number of Nocturnal Awakenings During the Last 2 Weeks of Treatment — 2.1; 10.0 number of nocturnal awakenings
Phase 2 N=26 50 Hz Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Parkinson's Disease
Parkinson Disease
Primary: Gait Speed — 7.54; 8.20; 8.31; 9.32 seconds
Phase 2 N=8 Efficacy and Safety of Filgrastim in Alzheimer's Disease
Alzheimer's Disease
Primary: Cognitive Measures Incluing ADAScog, Selected CANTABS Tests (Paired Associate Learning (PAL)and PAL ) — 22.25; 22.25; 20.5; 17.75 units on a scale
Phase 2 N=71 Bortezomib With or Without Irinotecan in Treating Patients With Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Recurrent Squamous Cell Carcinoma of the Hypopharynx · Recurrent Squamous Cell Carcinoma of the Larynx · Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity
Primary: Response Rate on Step 1 — 13.1; 2.6 percentage of participants
Phase 2 N=34 Effect of Lithium Carbonate on Low-Dose Radioiodine Therapy in Early Thyroid Cancer
Thyroid Cancer · Differentiated Thyroid Carcinoma
Primary: The Rate of Successful Thyroid Ablation as Defined by Negative Recombinant Human Thyrotropin (rhTSH) Stimulated Radioiodine Whole Body Scan (RAI WBS) at 1 Year. — 10; 10…
Phase 2 N=25 Transcranial Direct Current Stimulation to Treat Symptoms of Parkinson's Disease
Parkinson Disease
Primary: Gait Speed Before and After Real and Sham tDCS. — 8.7; 8.6; 9.7; 9.5 Seconds
Phase 2 N=44 Gemcitabine and Imatinib Mesylate as First-Line Therapy in Patients With Locally Adv. or Metastatic Pancreatic Cancer
Pancreatic Cancer
Primary: Progression-free Survival — 3.9 months
Phase 2 N=124 Ixabepilone in Treating Patients With Metastatic Prostate Cancer
Adenocarcinoma of the Prostate · Recurrent Prostate Cancer · Stage IV Prostate Cancer
Primary: Proportion of Patients With PSA Response — 0.33; 0.24; 0.18 Proportion of participants